NBRV - Nabriva Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Nabriva Therapeutics plc

25-28 North Wall Quay
IFSC
Dublin 1
Ireland
353 1 649 2000
http://www.nabriva.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees110

Key Executives

NameTitlePayExercisedYear Born
Mr. Theodore R. SchroederCEO & Director240.74kN/A1955
Mr. Steven P. GelonePres & COO568.04kN/A1968
Dr. Colin BroomConsultant & Director870.84kN/A1956
Mr. Francesco Maria LavinoChief Commercial Officer565.99kN/A1973
Mr. Gary L. SenderChief Financial OfficerN/AN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections, as well as Pediatric oral formulation. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Nabriva Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.